[ Price : $8.95]
FDA says Lillys bebtelovimab is not authorized for use in any U.S. region because it is not active against two key Omicron subvari...[ Price : $8.95]
Eisai and Biogen report new data from a lecanemab Alzheimers Phase 3 trial that suggest treated patients with early Alzheimers dis...[ Price : $8.95]
FDA approves Ferring Pharmaceuticals Rebyota (fecal microbiota) for preventing recurrence of Clostridioides difficile infection in...[ Price : $8.95]
A former Becton Dickinson safety official petitions FDA to refer the company to the U.S. Justice Department for allegedly violatin...[ Price : $8.95]
FDA warns Arbor Centers for EyeCare about objectionable conditions in its conduct of two clinical investigations.[ Price : $8.95]
Federal Register notice: FDA makes available a final guidance entitled Enforcement Policy Regarding Investigational New Drug Requi...[ Price : $8.95]
Lexicon asks that its NDA for sotagliflozin be approved to treat Type 1 diabetes or that a hearing be held to resolve issues of fa...[ Price : $8.95]
Five stakeholders recommend changes to an FDA proposed rule on nonprescription drug products with an additional condition for nonp...